Search This Blog

Wednesday, January 15, 2020

Ad Com meeting tomorrow on Durect’s bupivacaine

The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee will meet tomorrow, January 16, to review and discuss DURECT’s (NASDAQ:DRRX) marketing application for bupivacaine extended-release solution for post-surgical analgesia.
Shares up 4% premarket on modest volume.
Meeting materials
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)